Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agios Pharmaceuticals Inc (NASDAQ:AGIO)

43.93
Delayed Data
As of Jul 26
 +1.62 / +3.83%
Today’s Change
33.50
Today|||52-Week Range
115.39
-32.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.6B

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Information

Agios Pharmaceuticals, Inc.
38 Sidney Street
Cambridge Massachusetts 02139-4169
P:(617) 649-8600
Investor Relations:
(617) 649-8299

Employees

Shareholders

Mutual fund holders64.79%
Individual stakeholders36.11%
Other institutional20.38%

Top Executives

David Paul SchenkeinPresident, Chief Executive Officer & Director
Glenn GoddardSenior Vice President-Finance & Contact Person
Scott BillerChief Scientific Officer
Chris BowdenChief Medical Officer
Shin-San Michael SuSenior Vice President-Research & Development